Volatile Organic Compounds (VOCs) in Active Inflammatory Bowel Disease

Description

Inflammatory Bowel Disease (IBD) are chronic diseases of the gut comprising Crohn's Disease (CD) and Ulcerative Colitis (UC). The symptoms of IBD consist of diarrhea, abdominal discomfort, weight loss, fatigue and rectal bleeding. However, symptoms and treatment vary between patients. Early management of IBD can lead to better response rates and decrease the risk of irreversible bowel damage and future disease complications such as surgeries. Current clinical tools for diagnosis and or assessing progression of IBD are either invasive (colonoscopy), have low patient acceptance (fecal calprotectin) or low accuracy (C-reactive protein). The purpose of this study is to collect clinical data and samples (including blood, breath and stool) donated by patients with IBD and patients with no IBD (controls) to facilitate research that may result in the development of new non-invasive methods of diagnosing IBD and understand the progression of the disease over time in order to better manage IBD patients.

Conditions

IBD, Crohn Disease, Ulcerative Colitis

Study Overview

Study Details

Study overview

Inflammatory Bowel Disease (IBD) are chronic diseases of the gut comprising Crohn's Disease (CD) and Ulcerative Colitis (UC). The symptoms of IBD consist of diarrhea, abdominal discomfort, weight loss, fatigue and rectal bleeding. However, symptoms and treatment vary between patients. Early management of IBD can lead to better response rates and decrease the risk of irreversible bowel damage and future disease complications such as surgeries. Current clinical tools for diagnosis and or assessing progression of IBD are either invasive (colonoscopy), have low patient acceptance (fecal calprotectin) or low accuracy (C-reactive protein). The purpose of this study is to collect clinical data and samples (including blood, breath and stool) donated by patients with IBD and patients with no IBD (controls) to facilitate research that may result in the development of new non-invasive methods of diagnosing IBD and understand the progression of the disease over time in order to better manage IBD patients.

Non-invasive Disease Activity Monitoring in Patients With Inflammatory Bowel Disease (IBD) Using Volatile Organic Compounds

Volatile Organic Compounds (VOCs) in Active Inflammatory Bowel Disease

Condition
IBD
Intervention / Treatment

-

Contacts and Locations

Cleveland

Cleveland Clinic, Cleveland, Ohio, United States, 44195

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Diagnosed as having Crohn's Disease or Ulcerative Colitis
  • * Aged 18-70 years.
  • * Understands the language and signs an informed consent form.
  • * Any disease location, except isolated upper GI Crohn's disease only
  • * Any CD or UC disease activity.
  • * Outpatients and inpatients
  • * Patients will be recruited, and samples obtained at least one day, and no more than one week, prior to out/inpatient colonoscopy preparation to allow objective assessment of disease activity.
  • * Status post colectomy
  • * Status post diverting loop ileostomy or end ileostomy or colostomy
  • * On antibiotics in the past 3 months or currently
  • * Women (pregnant or breast feeding)
  • * Subjects with concurrent chronic liver, renal, lung or metabolic disorders
  • * Active malignancy
  • * Bowel preparation at day of sample procurement
  • * Isolated upper GI Crohn's disease only
  • * Active disease on colonoscopy, but normal fecal calprotectin at inclusion
  • * C diff. positive at time of inclusion (test to be obtained in routine clinical care).

Ages Eligible for Study

18 Years to 70 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

The Cleveland Clinic,

Florian Rieder, MD, PRINCIPAL_INVESTIGATOR, The Cleveland Clinic

Study Record Dates

2025-09-30